Semi-Annual Report — FY2026 H1
What Solasia Pharma K.K. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-13View the original on EDINET
How much it says
51Typical
What moved here
15named for the first time
Its own wording
27terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue recognition for Sancuso product sales was scheduled for the third quarter because documentation relating to the change to China sales partner MAAB remained outstanding. Episil, meanwhile, became ready for sale in Brazil, while SP-05 received authorization to initiate its Phase Ib/II trial and disclosed plans to begin the Phase II portion following determination of the dose level. Research and development spending continued, resulting in both an operating loss and an interim loss, each shown as a negative figure.
Komori's summary of this document, not the document's own words.51Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 39 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
45
Typical
60
Detailed
62
Detailed
0
Almost nothing
15
Almost nothing
72
Detailed
55
Typical
100
Very detailed
7
Almost nothing
35
Thin
50
Typical
R&D spend2億円Money spent making new things.
Cash left over-4億円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.